Out-of-Pocket Spending for Health Care After COVID-19 Hospitalization
For most patients who survive COVID-19 hospitalization, out-of-pocket spending within 180 days of discharge is modest. However, 1 in 10 have out-of-pocket spending exceeding $2000.
Value in Cancer Care: An Economist's Perspective
Measuring the quality of oncology care and associating it with reimbursement, and high drug prices remain important concerns of value-based outpatient cancer care. A healthcare economist reviews the current status and suggests a potential path forward.
Three Proposals to Reform the 340B Drug Discount Program
The 340B Drug Discount Program has rapidly expanded over the last few years and may be missing its original intent. Here are 3 possible steps that could enhance the program’s function and mirror Congress’ original intent to enhance access for the poor to essential medical services.
Infused Chemotherapy Use in the Elderly After Patent Expiration
As calls for improving the quality and cost efficiency of oncology increase, future empirical work is needed to examine the responsiveness of oncologists' treatment decision making to incentives among patients of all ages and insurance types.
2 Commerce Drive Cranbury, NJ 08512